Home Forums Melanoma Diagnosis: Stages I &II New Melanomas Likely to Recur at Same Rate

  • This topic is empty.
Viewing 4 posts - 1 through 4 (of 4 total)
  • Author
    Posts
  • #22132
    cohanja
    Participant

    New Melanomas Likely to Recur at Same Rate

    Published: Aug 9, 2014

    By Charles Bankhead, Staff Writer, MedPage Today

    CHICAGO — A diagnosis of in situ or invasive melanoma conferred a similar long-term risk of invasive melanoma recurrence, a 40-year retrospective review showed.

    For the first 2 years after initial diagnosis, invasive melanoma had a greater risk of invasive recurrence, as compared with an initial diagnosis of in situ disease. Thereafter, the risk of invasive recurrence remains the same, regardless of the initial diagnosis, Hyemin Pomerantz, MD, of Brown University in Providence, R.I., reported here at the American Academy of Dermatology summer meeting.

    “The findings suggest that follow-up after diagnosis of in situ or invasive melanoma should be the same,” Pomerantz told MedPage Today. “Because the incidence of melanoma in situ is increasing, surveillance for recurrence in this patient population could help improve outcomes for melanoma.”

    The incidence of melanoma has increased steadily since the 1980s. Previous studies have shown that a diagnosis of in situ melanoma increases the risk of subsequent invasive recurrence as compared with the general population. However, the risk of invasive recurrence associated with in situ melanoma had not been compared with the risk of recurrence in patients who have a history of invasive melanoma, Pomerantz said.

    To compare recurrence risk associated with the initial diagnosis, investigators reviewed data from the Surveillance, Epidemiology, and End Results program for 1973 to 2011. They identified all patients with a first diagnosis of melanoma and no history of other types of cancer and determined the classification of the initial diagnosis (in situ, local invasive, or regional/distant invasive).

    The primary outcome of interest was invasive recurrence of melanoma at least 2 months after the initial melanoma diagnosis.

    The analysis comprised 55,661 patients with an initial diagnosis of melanoma in situ, 97,614 patients with local invasive melanoma, and 14,999 patients with regional/distant disease at initial diagnosis. Follow-up duration averaged 5.7 years for the regional/distant group, 8.3 years for the in situ group, and 10.7 years for the local invasive group.

    The in situ group had 1,936 invasive recurrences and an incidence rate of 4.2 cases per 1,000 person-years. That compared with incidence rates of 3.7 per 1,000 person-years for the local invasive group and 4.7 per 1,000 person-years for the regional/distant group.

    The patients with melanoma in situ diagnoses served as the reference group for the analysis (hazard ratio 1.0). For all three groups combined, the hazard for invasive recurrence was 1.04 (95% CI 0.99-1.10). The localized group had a hazard of 1.03 (95% C 0.97-1.09) and the regional/distant group had a hazard ratio of 1.08 (95% CI 1.02-1.14).

    Pomerantz and colleagues then examined the risk of invasive recurrence by duration from the initial diagnosis. The results showed an initial diagnosis of local invasive or regional/distant disease significantly increased the likelihood of invasive recurrence only during the first 2 years:

    2 months to 1 year: in situ HR 1.0, localized 1.31 (95% CI 1.11-1.54), regional/distant 1.75 (1.37-2.24)

    1 to 2 years: 1.0, 1.17 (0.99-1.39), 1.42 (1.07-1.89)

    2 to 5 years: 1.0, 1.07 (0.96-1.19), 1.21 (0.98-1.51)

    5 to 10 years: 1.0, 1.02 (0.92-1.14), 1.01 (0.79-1.29)

    The results make a case for following patients with in situ melanoma as frequently and for the same duration as patients with invasive melanoma, particularly localized invasive melanoma, Pomerantz said.

    #65165
    barb3246
    Participant

    Is this referring to the likelihood that an in-situ lesion that has already been treated with a WLE will recur in the same location as the WLE but invasive and not in-situ ?

    #65166
    momof4
    Participant

    What does this mean? My dermatologist told me that melanoma in-situ was 100% cured with excision and had no chance of recurrence. This article is saying melanoma in-situ has a recurrence rate the same as invasive? Can someone explain what all this means? Thank you!

    #65167
    Catherine Poole
    Keymaster

    Insitu means in place, and therefore the melanoma cannot metastasize. I think this study is saying that despite being insitu, follow up is important, nothing more. Please don’t get you worrying!~

Viewing 4 posts - 1 through 4 (of 4 total)
  • The forum ‘Melanoma Diagnosis: Stages I &II’ is closed to new topics and replies.